Law360, New York (March 08, 2010, 6:37 PM ET) -- Six plaintiffs seeking to certify indirect purchaser classes in multidistrict litigation accusing Purdue Pharma LP of excluding generic competition for the painkiller OxyContin by engaging in sham patent infringement litigation have resolved their claims with the drugmaker.
In separate stipulations filed Monday in the U.S. District Court for the Southern District of New York, the Connecticut Citizen Action Group, along with five individual OxyContin consumers, agreed to dismiss their complaints with prejudice, with all parties to bear their own costs and attorneys' fees.
Additional details of...
OxyContin Buyers Resolve Purdue Antitrust Claims
To view the full article, take a free trial now.
